Hybio Pharmaceutical (SHE:300199) said its HY3003 injection clinical trial application has been accepted by China's medical products regulator.
The product is intended for long-term weight management in adults, according to a Friday filing with the Shenzhen bourse.
Shares of the pharmaceutical company were down 4% in recent trade.